Biotech Roundup: Moonshots, Pink Slips, Gilead, Brexit & More
Xconomy
JULY 1, 2016
At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said it would take a shot at restructuring the way it evaluates oncology products. Gilead Sciences has been a target of drug-price criticism for its hepatitis C treatments, but it dialed back the price of its new one.
59 
Let's personalize your content